Navigation Links
In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia
Date:1/12/2009

MARSEILLE, France, January 12 /PRNewswire-FirstCall/ -- IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a cancer profiler that develops and markets molecular diagnostic products for leukemia and breast cancer has launched 3 new products during the fourth quarter of 2008, that expand its leukemia molecular diagnostic portfolio:

    - FusionQuant BCR-ABL IVD kit, used in the the detection and monitoring
      of chronic myeloid leukemias (CML), is a new CE marked expanded
      version of our existing product. The new IVD kit now provides all the
      necessary components in one package adding convenience and efficiency
      in the lab. The improved kit will also support the much needed test
      standardisation required for proper disease monitoring

    - ProfileQuant CLLU1, in chronic lymphocytic leukemia (CLL).
      This research kit provides prognostic information, and has the
      potential to play a significant role in the monitoring of this disease.

    - MutaScreen MPL, a research kit for the detection of MPL mutations in
      JAK2 negative myeloproliferative neoplams (MPN), is a significant
      addition to the MPD family of products that Ipsogen offers.

These 3 new tests exemplify Ipsogen's strategy of (i) introducing technological and scientific innovation to address unmet diagnostic needs, and (ii) rapidly translating scientific discoveries into patient bedside tools, in line with the ultimate objective of enabling better and more personalised disease management.

"In the last quarter of 2008, we launched 3 new products. With 21 kits now in distribution, of which 10 are CE marked, Ipsogen's molecular diagnostic portfolio covers a significant range of the leukemia spectrum. These new products will help hematologists refine and improve treatment strategies" says Stephane Debono, COO and in charge of product planning..

Vincent Fert, CEO, concludes: 'These 3 new product launches are in line with our 2008 plans, and will further equip our sales staff with a comprehensive and market leading range of leukemia products that helps consolidate our leadership position in this growing market'.

Next Press Release announcement - Full-year Sales 2008: 18 February 2009 (after market)

About IPSOGEN

Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

With more than 70 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that remained unavailable until now.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society.

Ipsogen employed 48 people as of December 31, 2008. Its headquarters are located in Marseilles, France. The company has also a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit: http://www.ipsogen.com


'/>"/>
SOURCE Ipsogen SA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
2. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
3. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
4. Beckman Coulter Announces Second Quarter 2008 Earnings to be Released on Friday, July 25, 2008, Before Market Opens
5. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
6. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
7. Sales of Stem Cell Products Expected to Reach $87 Million in 2008, Leading Medical Industry Analyst Says
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
10. Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy
11. Sparta Systems Demonstrates Global Enterprise Quality Management Leadership at TrackWise(R) Connection User Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
(Date:4/28/2016)... The report "Cryocooler Market by ... (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, and ... 2022", published by MarketsandMarkets, the global market is expected ... a CAGR of 7.29% between 2016 and 2022. ... Figures spread through 159 Pages and in-depth TOC on ...
(Date:4/28/2016)... Connecticut (PRWEB) , ... April 28, 2016 , ... ... Group, Inc., will hold an open house for regional manufacturers at its Maple ... displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading ...
(Date:4/27/2016)... VANCOUVER, British Columbia , April 27, 2016 ... "Gesellschaft" oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... sie im Anschluss an ihre Pressemitteilung vom 13. ... Inc. erhalten hat, ihre Finanzen um zusätzliche 200.000.000 ... auf 4.000.000 Kanadische Dollar zu bringen. Davon wurden ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):